((自动化翻译由路透提供，请见免责声明 ))
10月30日 - ** Blueprint Medicines 股价上涨7.98%，至90.06美元；开盘价创两个月新高，随后跌幅收窄
** 该公司提高了其胃肠道癌症药物AYVAKIT在24财年的净产品收入预期
** 公司目前预计，2024年AYVAKIT的全球净产品收入约为4.75亿至4.8亿美元，高于之前的4.35亿至4.5亿美元。
** 这一更新的展望是基于接受治疗的患者人数持续增长、合规性和其他业绩因素持续向好，以及美国以外地区的业绩强于预期。
** BPMC 公布第三季度税前利润为 560.03 亿美元，低于预期的 6100 万美元--LSEG
** 该股的平均评级为 "买入 "或更高，中位预测价格为 128 美元。
** 包括本交易日走势在内，该股今年累计下跌约 3
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.